Stayble Therapeutics AB (publ)
STO: STABL.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andreas Gerward
- Employees
- 2
- Headquarters
- Gothenburg, Sweden
- IPO year
- 2020
- Market cap
- SEK 21.1M
- Website
- https://www.staybletherapeutics.se
Loading STABL…
Loading profile data…Frequently asked questions about STABL
What does Stayble Therapeutics AB (publ) (STABL.ST) do?
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Where does STABL.ST trade?
Stayble Therapeutics AB (publ) (STABL.ST) trades on the Stockholm Stock Exchange.
What sector is STABL.ST in?
Stayble Therapeutics AB (publ) (STABL.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Stayble Therapeutics AB (publ)?
Andreas Gerward is the chief executive officer of Stayble Therapeutics AB (publ) (STABL.ST).
Where is Stayble Therapeutics AB (publ) headquartered?
Stayble Therapeutics AB (publ) is headquartered in Sweden.
Does STABL.ST pay a dividend?
Stayble Therapeutics AB (publ) (STABL.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did STABL.ST go public?
Stayble Therapeutics AB (publ) (STABL.ST) completed its initial public offering in 2020.